The Journal of dermatological treatment · 2007
Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Antonucci Angela, Negosanti Massimino, Tabanelli Michela, Varotti Claudio
Аннотация
BACKGROUND: Pemphigus vulgaris is an autoimmune disease characterized by blisters and widespread erosions, involving skin and mucous membranes, caused by autoantibodies to desmoglein 1 and 3. This pathology is associated with increased morbidity and mortality if untreated. The treatment of pemphigus vulgaris requires multiple immunosuppressive agents, but often it is particularly resistant.
OBJECTIVE: To evaluate the efficacy and safety of rituximab therapy in refractory pemphigus vulgaris.
METHODS: Five patients diagnosed as having pemphigus vulgaris were treated with anti-CD20 monoclonal antibody (rituximab). Each patient was treated with rituximab intravenously at a dosage of 375 mg per square metre of body surface area once weekly for 4 weeks.
RESULTS: All the patients presented clinical resolution. No adverse effects were observed. It is important to observe the clinical evolution in the future, but our experience is still limited to a short lifetime and follow-up.
CONCLUSION: In our experience rituximab has been an effective and safe treatment for refractory pemphigus vulgaris.
OBJECTIVE: To evaluate the efficacy and safety of rituximab therapy in refractory pemphigus vulgaris.
METHODS: Five patients diagnosed as having pemphigus vulgaris were treated with anti-CD20 monoclonal antibody (rituximab). Each patient was treated with rituximab intravenously at a dosage of 375 mg per square metre of body surface area once weekly for 4 weeks.
RESULTS: All the patients presented clinical resolution. No adverse effects were observed. It is important to observe the clinical evolution in the future, but our experience is still limited to a short lifetime and follow-up.
CONCLUSION: In our experience rituximab has been an effective and safe treatment for refractory pemphigus vulgaris.